- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00346567
Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)
February 22, 2016 updated by: Rigshospitalet, Denmark
Clinical Trial: Backup With Combivir (AZT/3TC) or Single Dose (sd) Truvada (FTC/TDF) in Order to Avoid NNRTI Resistance After sd Nevirapine for the Prevention of Mother-to-child Transmission (MTCT)
The aim of the study is to find short course alternatives to single dose (sd)nevirapine for the prevention of mother-to-child HIV-transmission with the same or better degree of transmission protection than sd nevirapine but with less NNRTI resistance development.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Randomised open study comparing Zidovudine from 28 weeks gestation, single dose Nevirapine + 1 week of Combivir with Zidovudine from 28 weeks gestation, single dose Nevirapine + single dose of Truvada for the mothers during birth.
In both arms the infants will receive one dose of nevirapine within the first days after births as well as 7 to 28 days Zidovudine.
N = 450.
The study will be conducted at Ngamiani and Makorora Health Centres and Bombo Regional Hospital in Tanga, Tanzania as a cooperation between Rigshospitalet, Denmark, University of Copenhagen and National Institute of Medical Research, Tanzania.
Study Type
Interventional
Enrollment (Actual)
566
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tanga, Tanzania
- Bombo Regional Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- HIV infected, antiretroviral naive, not fulfilling national Tanzanian criteria for HAART treatment, giving informed consent, consenting to homevisit-follow-up in case of no-show for scheduled hospital visit.
Exclusion Criteria:
- CD4 less than 350 x10(6)/L, suffering from systemic diseases in need of medical treatment e.g. TB, renal or liver failure etc.
- Creatinin higher than 1,5 mg/dL, Alanine aminotransferase above 140 U/L
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
AZT from week 28 or asap thereafter.
Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
|
|
Experimental: 2
AZT from week 28 or asap thereafter.
Intrapartum Single dose Truvada + Single dose NVP
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
frequency of mother-to-child HIV transmission
Time Frame: 6 weeks post partum
|
6 weeks post partum
|
frequency of NNRTI resistance development
Time Frame: 6 weeks post partum
|
6 weeks post partum
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison of p24 antigen to HIV RNA for treatment induced changes in viremia
Time Frame: Delivery, day 7, day 42 and month 9 post partum
|
Delivery, day 7, day 42 and month 9 post partum
|
Comparison of p24 antigen ability to detect viremia for the various subtypes A,C & D
Time Frame: Delivery, Day 7, Day 42 post partum, mother, Day 42 and Day 90 post partum child
|
Delivery, Day 7, Day 42 post partum, mother, Day 42 and Day 90 post partum child
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Terese L Katzenstein, MD Ph.D., Rigshospitalet, Denmark
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
June 29, 2006
First Submitted That Met QC Criteria
June 29, 2006
First Posted (Estimate)
June 30, 2006
Study Record Updates
Last Update Posted (Estimate)
February 23, 2016
Last Update Submitted That Met QC Criteria
February 22, 2016
Last Verified
February 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Tenofovir
- Emtricitabine
- Lamivudine
- Zidovudine
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Lamivudine, zidovudine drug combination
Other Study ID Numbers
- comtru
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Zidovudine and Lamivudine (Combivir)
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University of...Completed
-
Gilead SciencesCompletedHIV InfectionsUnited Kingdom
-
Hospital Clinic of BarcelonaCompleted
-
National Institute of Allergy and Infectious Diseases...Agouron Pharmaceuticals; Glaxo Wellcome; Chiron CorporationCompletedHIV InfectionsUnited States
-
Kirby InstituteNational Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney and other collaboratorsCompletedGlucose Metabolism Disorders | Metabolic Diseases | HIV Infections | Cardiovascular Disease | Dyslipidemias | LipodystrophyAustralia
-
St. Luke's-Roosevelt Hospital CenterGilead SciencesCompleted
-
ANRS, Emerging Infectious DiseasesAbbottCompleted
-
Glaxo WellcomeUnknownHIV InfectionsUnited States
-
Glaxo WellcomeCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Completed